<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5370">
  <stage>Registered</stage>
  <submitdate>2/02/2016</submitdate>
  <approvaldate>2/02/2016</approvaldate>
  <nctid>NCT02676869</nctid>
  <trial_identification>
    <studytitle>Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma</studytitle>
    <scientifictitle>A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab</scientifictitle>
    <utrn />
    <trialacronym>TACTI-mel</trialacronym>
    <secondaryid>IMP321-P012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stage IV Melanoma</healthcondition>
    <healthcondition>Stage III Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IMP321
Treatment: drugs - Pembrolizumab

Experimental: IMP321 dose escalation - IMP321 administered fortnightly in addition to SOC pembrolizumab.


Treatment: drugs: IMP321
Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks

Treatment: drugs: Pembrolizumab
Administered according to the approved label.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of patients with treatment emergent adverse events, serious adverse events and dose limiting toxicities.</outcome>
      <timepoint>From the time of inform consent form signature until 30 days after end of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events evaluated according to the current National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v4.03)</outcome>
      <timepoint>From the time of inform consent form signature until 30 days after end of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate according to RECIST 1.1</outcome>
      <timepoint>At 6 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate according to irRC</outcome>
      <timepoint>At 6 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>At 6 and 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          1. Able to give written informed consent and to comply with the protocol

          2. Histologically confirmed diagnosis of locally advanced (unresectable Stage III) or
             metastatic (Stage IV) melanoma

          3. Currently receiving anti-PD-1 therapy with pembrolizumab and after 3 cycles achieved
             asymptomatic irPD (slowly progressive, not requiring urgent intervention, and stable
             performance status) or sub-optimal response (irSD, irPR) as demonstrated in imaging
             assessments performed within 6 weeks prior to day 1 of cycle 5 of pembrolizumab.

          4. Female or male 18 years of age or above

          5. All patients with reproductive potential must agree to use effective contraception
             from time of study entry until at least 4 months after the last administration of
             study treatment.

          6. ECOG performance status 0-1

          7. Expected survival longer than three months

          8. Resolution of toxicity associated with prior or current therapy to grade &lt; 2 (except
             for alopecia and transaminases in case of liver metastases)

          9. Evidence of measurable disease as defined by Response Evaluation Criteria in Solid
             Tumours (RECIST) version 1.1

         10. Laboratory criteria:

               -  Absolute neutrophil count &gt; 1.5 x 109/L

               -  Platelet count = 100 x 109/L

               -  Haemoglobin &gt; 9 g/dL or 5.58 mmol/L

               -  Serum creatinine = 1.5 Ã— ULN

               -  Total bilirubin &lt; 20 mmol/L, except for familial cholemia (Gilbert's disease)

               -  Serum AST (=GOT) and ALT (=GPT) &lt; 3 times the upper limit of normal or &lt; 5 times
                  upper limit of normal if liver metastases are present</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          1. More than four prior lines of therapies for advanced or metastatic disease.

          2. Prior PD-1/PDL-1 targeted therapy

          3. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue

          4. Currently receiving treatment with another investigational drug, or less than 4 weeks
             since ending treatment on another investigational drug

          5. Currently receiving systemic chemotherapy, targeted small molecule therapy,
             radiotherapy, or biological cancer therapy (other than pembrolizumab) or less than 4
             weeks since completion of these therapies and first dose of study treatment

          6. History of irAEs from ipilimumab of CTCAE Grade 4 requiring steroid treatment

          7. Known cerebral or leptomeningeal metastases. (Some subjects with previously treated
             brain metastases may participate under specific circumstances)

          8. Women who are pregnant or lactating

          9. Serious intercurrent infection within 4 weeks prior to first dose of study treatment

         10. Evidence of severe or uncontrolled cardiac disease (NYHA III-IV) within 6 months prior
             to first dose of study treatment

         11. Active acute or chronic infection

         12. History or evidence of interstitial lung disease or active non-infectious pneumonitis

         13. Active auto-immune disease requiring immunosuppressive therapy

         14. HIV positivity

         15. Active hepatitis B or hepatitis C, currently treated with antiviral therapy

         16. Life threatening illness unrelated to cancer

         17. Previous malignancies within the last three years other than melanoma

         18. Any current disorder that would impede the patient's ability to provide informed
             consent or to comply with the protocol

         19. Continuous systemic treatment with either corticosteroids or other immunosuppressive
             medications within 4 weeks prior to first dose of study treatment

         20. History or evidence of severe allergic episodes and/or angioedema

         21. Any current disorder likely to modify absorption, distribution or elimination of
             IMP321

         22. Alcohol or substance abuse disorder

         23. Known hypersensitivity to any of the components of IMP321

         24. Unwilling or unable to follow protocol requirements

         25. In the clinical judgment of the investigator, the patient is unsuitable for
             participation in this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Brisbane Womens Hospital - Brisbane</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Greenslopes Private Hospital - Brisbane</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>Fiona Stanley Hospital - Perth</hospital>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>4120 - Brisbane</postcode>
    <postcode>5042 - Adelaide</postcode>
    <postcode>3181 - Melbourne</postcode>
    <postcode>6150 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Prima BioMed Australia Pty. Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Prima BioMed Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability and recommended phase 2
      dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients
      with unresectable or metastatic melanoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02676869</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Prima BioMed</name>
      <address />
      <phone />
      <fax />
      <email>tactimel@primabiomed.com.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>